Editorial Team

Bhavish Agarwal

Bhavish Agarwal is the founder of Atlas and previously worked at Google and Microsoft. He has spent the past several years building regulatory data infrastructure for the pharmaceutical industry.

Latest Articles

CAPA Guide 2026

Atlas

Regulatory Intelligence

CAPA in Pharma and Medical Devices: Corrective and Preventive Action Guide (2026)

CAPA stands for Corrective and Preventive Action: the quality system process that finds the cause of a problem, removes it, and proves it will not recur. This guide covers the definition, corrective vs preventive action, the process step by step, root cause tools, effectiveness checks, the drug and device requirements (21 CFR 211.192, 211.22 and ISO 13485 under QMSR), supplier CAPA, and what FDA cites most, using Atlas inspection data.

510(k) submission guide: the path from predicate to clearance and what FDA inspects after

Regulatory Intelligence

510(k) submission guide: what a 510(k) is, how FDA reviews it, and what inspectors check after clearance

A 510(k) is the premarket notification a device maker files with FDA to show a new device is substantially equivalent to a legally marketed predicate. This guide covers who must submit, the exemptions, Traditional, Special and Abbreviated 510(k)s, eSTAR, acceptance review and Additional Information holds, the 90 FDA day decision goal, how 510(k) compares with De Novo and PMA, when a change to a cleared device needs a new 510(k), and what Atlas data on 389 device Form 483s from 2026 shows about the design changes inspectors check after clearance.

API manufacturer FDA Form 483s 2025 to 2026: by country and most cited sections versus finished dose

Regulatory Intelligence

API 483s: what FDA cites at active pharmaceutical ingredient manufacturers, 2025 to 2026

How FDA inspects active pharmaceutical ingredient manufacturers under FD&C Act section 501(a)(2)(B), Compliance Program 7356.002F and ICH Q7, how API Form 483 observations are written and coded, and what Atlas data show for 47 Form 483s issued at registered API facilities from January 2025 to July 2026: counts by country, the most cited sections, the comparison with 415 finished-dose 483s, and when an API 483 turns into a warning letter.

Baxter FDA Warning Letter 2026

Atlas

Regulatory Intelligence

Baxter FDA warning letter 2026: Round Lake, the four violations, and the 483s behind them

FDA's drug center sent Baxter a warning letter dated September 29, 2026 for its Round Lake, Illinois sterile injectables facility. This piece covers what the letter cites, the March to April 2026 inspection and Form 483 behind it, the earlier 483s at Round Lake, and the Form 483 record across 47 Baxter facility records in Atlas.

Regulatory Intelligence

Chlorthalidone recall 2026: two dissolution failures, the lots, and the manufacturer's FDA record

Chlorthalidone 25 mg tablets made by Inventia Healthcare in India and distributed by Rising Pharma were recalled twice in 2026, in June and September, for failed dissolution specifications. This piece covers the lots, what a dissolution failure means, the manufacturer's FDA inspection and Form 483 history, and what quality teams should check.

Cleaning validation FDA and EMA requirements, with 21 CFR 211.67 citation data

Regulatory Intelligence

Cleaning validation: FDA and EMA requirements, acceptance limits, and what 483s cite

What FDA and EMA require for cleaning validation: 21 CFR 211.67 and 211.182, FDA's 1993 inspection guide, ICH Q7 section 12.7, EU GMP Annex 15 and the EMA guideline on health-based exposure limits. Covers acceptance limits (HBEL/PDE, 1/1000 dose, 10 ppm), protocols, sampling, hold times and continued verification, with Atlas data on how often 211.67 appears on 2025 and 2026 human drug Form 483s.

Computerized system validation: OQ audit trail tests inspectors check

Compliance

Computerized system validation: OQ audit trail tests for life sciences

Computerized system validation is the documented, risk-based evidence that a regulated computer system works as intended and keeps its data trustworthy. This guide covers the expectations in FDA's CSA guidance, Part 11, EMA and ICH E6(R3), a seven-step lifecycle, concrete OQ audit trail test cases, vendor and periodic review controls, and Atlas data on how often FDA cites computerized systems and data integrity.

Continued process verification guide cover: drug Form 483s citing 21 CFR 211.110(a) average 7.9 observations

Regulatory Intelligence

Continued Process Verification (CPV): FDA Requirements, Metrics and a Review Checklist

Continued process verification is the ongoing monitoring that shows a validated commercial process stays in a state of control. This guide covers the FDA requirements behind CPV, how often drug 483s cite process monitoring, the metrics worth trending, review frequency, escalation rules, what two 2026 warning letters asked for, and a review checklist.

Corrective Action Requests.

Atlas

Regulatory Intelligence

What Is a Corrective Action Request (CAR)? Process, Form and ISO Rules

A corrective action request (CAR) is the internal document that assigns a nonconformity to an owner, who must find the root cause, fix it and prove the fix works. This guide covers when a CAR is raised, the CAR workflow step by step, what a CAR form contains, CAR vs SCAR vs CAPA, what ISO 9001 clause 10.2 and ISO 13485 clause 8.5.2 require, the metrics that show whether a CAR system works, and what 2026 FDA Form 483s cite when it does not.

Compliance

CSA vs CSV for life sciences: five stages inspectors can trace

Computer System Validation proves software works through specifications and scripted tests; Computer Software Assurance sizes the effort to risk. This guide covers FDA's four-step CSA approach, a five-stage governance model, how to apply it to EBR, MES and LIMS, hybrid strategies, the records inspectors ask for, and how often FDA cites computerized-system controls.

Data integrity citations on FDA Form 483s: which CFR sections FDA cites, 2025 to 2026

Regulatory Intelligence

Data integrity citations on FDA Form 483s: the sections FDA cites and how often, 2025 to 2026

What counts as a data integrity citation on an FDA Form 483, which 21 CFR sections FDA uses for it, what ALCOA and ALCOA+ mean in FDA's 2018 guidance, and how often data integrity sections appeared on 779 human drug Form 483s citing Part 211 from January 2025 to July 2026, with US and foreign rates and named examples.

Eurofins FDA Warning Letter

Atlas

Regulatory Intelligence

Eurofins FDA warning letter 2026: microbial data integrity at a contract testing lab

FDA's drug center sent Eurofins SF Analytical Laboratories a warning letter dated October 6, 2026 for incomplete microbiology data at its Horsham, Pennsylvania contract testing laboratory. This piece covers the three violations, the 2022 and 2026 Form 483s behind them, the inspection record of 71 Eurofins facility records in Atlas, how often 22 recent contract lab 483s cite data integrity sections, and what a sponsor should check at its own contract lab.

Regulatory Intelligence

Where to Find FDA 483 Reports (and How to Read One)

There are three routes to an FDA Form 483: FDA's FOIA electronic reading room, a FOIA request, or a searchable database. This guide compares them on coverage, wait time and search, then explains how to read a 483 once you have it, with three recent examples.

FDA 483 vs warning letter: the 15 working day response windows and what 4,584 Form 483s from 2025 show

Regulatory Intelligence

FDA 483 vs warning letter: who gets 15 working days to respond?

A Form FDA 483 is the investigator's list of observations at the close of an inspection. A warning letter is a formal advisory FDA issues later, after review, when it judges violations significant. This guide explains the 15 business day response window for each, how FDA escalates and closes out warning letters, what Atlas data on 4,584 Form 483s from 2025 shows, and how to write a response that survives verification.

FDA combination products: the three types, primary mode of action and the cGMP rules in 21 CFR Part 4

Regulatory Intelligence

Combination products: the FDA definition, PMOA and the Part 4 cGMP rules

A combination product combines a drug, device or biological product into one product, one package or a cross-labeled pair. This guide covers the FDA definition in 21 CFR 3.2(e), the three types with examples, how primary mode of action decides the lead center, the Request for Designation, the 21 CFR Part 4 cGMP options as rewritten for the QMSR, postmarketing safety reporting under Part 4 subpart B, and what Atlas found in 193 Form 483s issued to 15 combination product makers.

What 438 FDA Refusal Letters Say.

Atlas

Regulatory Intelligence

Complete response letter (CRL): what it is, what happens next, and the Form 483 link

A complete response letter (CRL) is the FDA's formal notice, under 21 CFR 314.110 and 601.3, that a drug or biologic application cannot be approved in its present form. This guide covers what the letter contains, the three options after a CRL (Class 1 or Class 2 resubmission, withdrawal, or a hearing), how a CRL differs from refuse to file and approval, how many CRLs FDA issued from 2024 to June 2026, why 42 of the 65 letters from 2024 cited facility inspections, and how a Form 483 at a contract filler turned into CRLs for Regeneron.

FDA Compounding Warning Letters 2026

Atlas

Regulatory Intelligence

FDA compounding warning letters in 2026: Empower, SCA and the 503A vs 503B split

What FDA's September 2026 warning letters to Empower Pharmacy (Houston, 503A) and SCA Pharmaceuticals (Little Rock, 503B) cite, how 503A pharmacies and 503B outsourcing facilities differ on CGMP and on compounding copies of approved drugs, when semaglutide and tirzepatide left the shortage list, and what 52 Form 483s issued at registered outsourcing facilities in 2025 and 2026 cite most.

FDA EIRs for QA Readiness.

Atlas

Regulatory Intelligence

FDA EIR (Establishment Inspection Report): What It Contains and How to Get One

The EIR, or Establishment Inspection Report, is the FDA investigator's full written account of an inspection. This guide compares it with the Form 483 and the classification letter, walks through each section of the report, explains when FDA releases it to the firm and to the public, shows how rare EIRs are in the public record using Atlas directory counts, and sets out how to read one for inspection readiness.

FDA foreign inspections: Form 483s issued outside the US by country, 2025 and 2026

Regulatory Intelligence

FDA foreign inspections in 2026: unannounced visits, the refusal rule, and the Form 483s by country

FDA inspects about 3,000 foreign facilities a year and now arrives at most Indian sites without notice. This guide covers the legal basis, what refusing or limiting an inspection triggers, 704(a)(4) records requests and Import Alert 66-79, and Atlas data on every Form 483 issued from January 2025 to July 2026 by country, including the regulations cited most often at Indian drug facilities.

What Is CGMP?

Atlas

Regulatory Intelligence

What Is CGMP? FDA Current Good Manufacturing Practice Explained

CGMP stands for Current Good Manufacturing Practice, the FDA regulations that set minimum requirements for the methods, facilities and controls used to make regulated products. This guide covers why the "C" matters, GMP vs CGMP, which CFR part applies to each product type, the 11 subparts of 21 CFR 211, the sections FDA cited most on 2026 drug Form 483s, and what follows a CGMP violation.

FDA inspection playbook: five phases from preparation to the Form 483 response, with front room and back room roles

Regulatory Intelligence

FDA inspection playbook: five phases from readiness to the EIR

A five-phase FDA inspection playbook for drug, biologics and device facilities: the readiness program, day 1 and the Form 482, front room and back room roles with a request log, the Form 483 close-out and annotation under IOM 5.5.11.4, and the 15 business day response, CAPA and EIR. Built on the 2026 IOM and Atlas Form 483 data from the August 15, 2026 release.

The four types of FDA inspections and how to tell them apart

Regulatory Intelligence

FDA inspection types: surveillance, for-cause, pre-approval and follow-up

FDA runs four types of inspections: surveillance, for-cause, application-based (pre-approval and pre-license) and follow-up. This guide explains what triggers each, how FDA picks sites for routine inspections, what a records request in lieu of inspection is, the day-of sequence from Form 482 to the EIR, and what 2,533 Form 483s issued in 2026 show about inspection team size and observation counts.

FDA Inspection Classifications: VAI, NAI, and OAI Explained

Regulatory Intelligence

NAI, VAI, OAI: What Each FDA Inspection Classification Means

Every FDA inspection ends with one of three classifications: NAI (no action indicated), VAI (voluntary action indicated) or OAI (official action indicated). This guide explains what each means, how FDA decides after a Form 483 and the company's response, how long the decision takes, what an OAI leads to, and how to look up any facility's classification history.

FDA Investigations Operations Manual (IOM): what investigators follow from arrival to close-out

Regulatory Intelligence

FDA IOM: what the Investigations Operations Manual tells investigators, and what it tells you

The Investigations Operations Manual (IOM) is the primary operational reference for FDA investigators. This guide covers the 2026 edition, its ten chapters, the Chapter 5 sections an inspected firm should read (credentials, Form FDA 482, refusals, photographs, samples, the Form 483 close-out and the EIR), how the IOM differs from the Compliance Program Guidance Manual and the Regulatory Procedures Manual, and what Atlas data show about the investigators who apply it.

US FDA investigators who inspect Indian facilities: 19 investigators across 292 Form 483s

Regulatory Intelligence

US FDA auditor list for India: the investigators behind 292 Form 483s, 2024 to 2026

FDA publishes no list of the investigators it sends to India. Atlas rebuilt one from 292 Form 483s issued to Indian facilities from January 2024 to July 2026: the 19 investigators named on five or more, the sections they cite, how FDA staffs India inspections through its New Delhi office and US-based investigators, and how a facility finds out who is coming.

KVK-Tech FDA Warning Letters.

Atlas

Regulatory Intelligence

KVK-Tech FDA warning letters: the 2020 letters, the 483s behind them and what followed

FDA sent KVK-Tech two warning letters in 2020: February 11 for test methods, investigations and lab data controls at 110 Terry Drive, and October 8 for cleaning validation and batch records at 100 Campus Drive. This piece sets the letters side by side, lays out the company's full inspection and Form 483 record from 2008 to 2025, and covers the 2021, 2022 and 2025 Form 483s and the 2024 DOJ resolution that followed.

FDA quality agreements: what owners and contract facilities must each control

Regulatory Intelligence

FDA Quality Agreements: What the Guidance Requires and Where Contracts Fail

A quality agreement is the written document in which a drug owner and a contract facility assign each CGMP activity. This guide covers what FDA's November 2016 guidance says, whether a quality agreement is required, a section-by-section checklist, how it differs from a supply agreement, how often 2025 and 2026 human drug Form 483s cite the quality unit section 21 CFR 211.22, and where agreements fail.

FDA Quality Metrics Program

Atlas

Regulatory Intelligence

The FDA quality metrics program in 2026: practice areas, QMM, and what Form 483s measure

What the FDA quality metrics program is, why reporting is still not required, the four practice areas FDA proposed in 2022 with their example metrics, how the program differs from CDER's voluntary Quality Management Maturity assessments, and which 21 CFR Part 211 sections FDA investigators cited in each practice area across 779 human drug Form 483s issued from January 2025 to July 2026.

FDA Untitled Letters Explained

Atlas

Regulatory Intelligence

FDA Untitled Letters: What They Are, Who Sends Them and What Follows

An FDA untitled letter is an advisory letter for violations that do not meet the threshold for a warning letter. This guide covers how the Regulatory Procedures Manual separates the two, which FDA offices send untitled letters, the 15 working day response OPDP asks for, how many OPDP letters FDA has posted each year since 2017, and how an untitled letter compares with a Form 483, a warning letter and a regulatory meeting.

FDA Violations and Warning Letters.

Atlas

Regulatory Intelligence

FDA Warning Letters: What They Mean, Common Violations and How to Respond

An FDA warning letter is the agency's formal notice that it found significant violations and expects them corrected. This guide covers where the letter sits on FDA's escalation ladder, what it contains, the regulations most often cited on the Form 483s that precede one (drugs and devices, from the Atlas directory), the 2026 Fresenius and Olympus letters, and how to respond inside 15 business days.

How to Navigate the FDA Warning Letters Database Successfully

Regulatory Intelligence

FDA Warning Letter Database: How to Search It and Trace a Letter to Its 483

FDA posts its warning letters in a searchable table on fda.gov. This guide shows how to search it by company, issuing office, subject and date, how to read closeout and response letters, what a warning letter contains, and how to connect any letter to the inspection and Form 483 that came before it, with four facility histories as worked examples.

FDA Warning Letters October 2026

Atlas

Regulatory Intelligence

FDA warning letters October 2026: all 18 drug and device CGMP letters

All 18 drug and device CGMP and QSR warning letters FDA posted in October 2026, with letter numbers, issue and posting dates, the 21 CFR sections cited, the five recipients already on Import Alert 66-40, and the Form 483 record Atlas holds for each inspected facility.

Fresenius FDA warning letters 2026: what the Ogden and Melrose Park letters say, and the 483s behind them

Regulatory Intelligence

Fresenius Kabi FDA warning letter 2026: Melrose Park, the Ogden letter, and the 483s behind them

Two Fresenius facilities received FDA warning letters within four weeks of each other in 2026. This piece explains what the Ogden, Utah and Melrose Park, Illinois letters cite, the Form 483s and inspections that preceded them, the group's wider enforcement record, and what the two cases have in common.

Hetero Labs FDA inspections: 34 Form 483s in 54 inspections across Hetero facilities

Regulatory Intelligence

Hetero Labs FDA inspection history: every unit, every 483, and where things stand

A unit-by-unit record of FDA inspections at Hetero Labs and Hetero Drugs facilities in India and the US: 54 inspections, 34 Form 483 outcomes, the citations FDA repeats, the 2017 Unit V warning letter and its 2022 closeout, the clean 2025 inspection at Vemagal, and the September 2025 inspections at Unit IX and Chinateenarla.

Supplier Qualification for FDA

Atlas

Regulatory Intelligence

Supplier Qualification: FDA Requirements, 8-Step Process and Checklist

Supplier qualification is the documented process of proving that a supplier can deliver material that meets your specifications, every lot. This guide sets out what FDA requires for drugs, APIs and devices, an 8-step qualification process, supplier risk tiers with typical audit frequency, a checklist, and Atlas Form 483 data (release of August 15, 2026) on how often investigators cite 21 CFR 211.84 and ISO 13485 clause 7.4.1.

Compliance

ICH Q9 quality risk management: what Q9(R1) requires in practice

ICH Q9 sets the principles for quality risk management (QRM) across the drug product lifecycle. This guide explains what the 2023 Q9(R1) revision changed, walks through the QRM process and formality tiers, shows how to link QRM to CAPA, change control and supplier oversight, and uses Atlas Form 483 data to show where weak risk management becomes a citation.

Import Alert 66-40 in 2026

Atlas

Regulatory Intelligence

Import Alert 66-40: the 2026 Rohto and TSP Solutions warning letters, and who else is on the list

What FDA Import Alert 66-40 is and how a foreign drug facility lands on it, with the two October 2026 warning letters that followed a 66-40 listing: Rohto Pharmaceutical (for its Rohto-Mentholatum facility in Vietnam, inspected in April 2026) and TSP Solutions in Singapore (reviewed through a 704(a)(4) records request). Includes an Atlas count of the 472 Red List entries by country as of the October 27, 2026 version, a comparison of import alerts and warning letters, and the steps FDA expects before removing a firm.

Medical device design controls under the QMSR: which design clauses FDA cited in 2026

Compliance

Medical device design controls under the QMSR: what FDA cites in 2026

Medical device design controls are the documented steps that turn user needs into a verified, validated device design. Since February 2, 2026, FDA enforces them through the QMSR and ISO 13485:2016 clause 7.3 instead of 21 CFR 820.30. This guide maps the old paragraphs to the new clauses, explains verification versus validation and the ISO 14971 risk link, covers what investigators ask for under Compliance Program 7382.850, and uses Atlas data on 389 device Form 483s from 2026 to show which design clauses FDA cites most.

Inspection Readiness

Mock FDA inspections: four formats for quality teams facing the 2026 QMSR

A mock FDA inspection tests your records, procedures, interviews and facility the way an investigator would, without regulatory authority. This guide covers choosing the right format, a ten-step sequence, the findings investigators cite most with Atlas data, converting findings into CAPA, and the 2026 QMSR changes for device mocks.

Mylan Viatris India FDA Record

Atlas

Regulatory Intelligence

Mylan Nashik and Viatris India: FDA inspection history, 483s and warning letters

The FDA inspection record of Mylan Laboratories Limited, the Viatris company, in India: nine facility records, 57 inspections, 35 ending with a Form 483. What FDA cited at Nashik in May 2024, the 2017 Nashik warning letter and its 2018 closeout, the December 2024 warning letter and Import Alert 66-40 at the Indore facility in Pithampur, and the regulations FDA cites most across Mylan's Indian sites.

Nonconformance: Types, NCR and Prevention

Atlas

Regulatory Intelligence

What Is a Nonconformance? Types, the NCR, and How FDA Cites It

A nonconformance (also written non-conformance or nonconformity) is any failure to meet a specified requirement. This guide covers the ISO 9000 definition, the critical, major and minor types with GMP examples, the fields of a nonconformance report (NCR), the disposition workflow from segregation to CAPA, how a nonconformance differs from a deviation, an OOS result and a CAPA, the regulations that govern it (ISO 13485 clause 8.3 under the QMSR, 21 CFR 211.192, 211.115 and 211.165(f)), and how often FDA cited these sections on 2026 Form 483s.

Olympus FDA Warning Letter 2026

Atlas

Regulatory Intelligence

Olympus FDA warning letter 2026: the six facilities, the 483s behind it, and the import alert

FDA's warning letter CMS 729208 to Olympus, dated October 7, 2026 and posted October 20, cites 12 violations at six device facilities. On October 20 FDA also added five Japan-made endoscope models to import alert 89-04. This piece lays out the letter, the late-2025 Form 483s behind it, the investigators, each facility's history, and what the import alert means for hospitals and device quality teams.

Pharmaceutical Regulatory Compliance

Atlas

Regulatory Intelligence

Pharmaceutical regulatory compliance: regulators, requirements and the cost of falling short

Pharmaceutical regulatory compliance means meeting the legal and quality rules that govern a drug from laboratory study to post-market safety reporting. This guide lists the main regulators and the rulebook each one enforces, maps the GLP, GCP, GMP, GDP and GVP stages, sets out what happens when a company falls short, from a Form 483 to a consent decree or a complete response letter, and shows which 21 CFR Part 211 sections FDA investigators cited most on human drug Form 483s from January 2025 to July 2026.

Regeneron FDA Form 483 in 2026: East Greenbush inspection and the CRLs tied to a third-party filler

Regulatory Intelligence

Regeneron FDA Form 483 in 2026: East Greenbush, Rensselaer and the filler CRLs

What is public about the January 2026 Form 483 at Regeneron's East Greenbush, New York facility, the inspection record of five Regeneron facilities in Atlas (39 inspections, 13 ending in a Form 483), the citations FDA has written at Rensselaer, and the July and October 2025 complete response letters that FDA tied to an inspection of the third-party filler Catalent Indiana.

Reliance Life Sciences Warning Letter

Atlas

Regulatory Intelligence

Reliance Life Sciences FDA warning letter 2026: Navi Mumbai data integrity, aseptic practice and the 483s behind it

FDA's drug center sent Reliance Life Sciences a warning letter dated August 18, 2026 for its Rabale, Navi Mumbai facility. This piece covers the two violations, the February 2026 inspection and Form 483 behind them, the recall and Import Alert 66-40 that came first, the facility's 11 FDA inspections and 7 Form 483s in Atlas, and how the findings compare with other Indian drug facilities.

Supplier Corrective Action Requests.

Atlas

Regulatory Intelligence

SCAR Meaning: The Supplier Corrective Action Request Process

A SCAR (Supplier Corrective Action Request) is the formal request a manufacturer sends a supplier to find and fix the root cause of a nonconformance. This guide covers the seven steps of the SCAR process, how a SCAR differs from a CAR and a CAPA, the drug and device regulations that require supplier control, when to escalate a supplier, and what 2026 Form 483s show about supplier findings.

Automating Regulatory Submissions.

Atlas

Regulatory Intelligence

eCTD 4.0 Timeline and Regulatory Submission Automation: What Changes in 2026

eCTD v4.0 is the ICH M8 version of the electronic Common Technical Document. This guide gives the eCTD 4.0 timeline for FDA, EMA, PMDA and Health Canada as of October 2026, explains what changes from v3.2.2, separates the submission tasks software can automate from the ones it cannot, and ends with a migration checklist. It also shows why the FDA refuses most applications over facilities, not formatting.

Atlas Compliance FAQ

Atlas

Inspection Readiness

Atlas Compliance FAQ: 10 Questions Quality Teams Ask Before They Buy

Atlas Compliance is an FDA inspection and enforcement intelligence platform for pharma and medical device quality teams. Ten questions buyers ask before choosing it, answered directly: data coverage, freshness, customers, security, onboarding, pricing, and ROI.

What Is an EDMS?

Atlas

Regulatory Intelligence

What is an EDMS? Electronic document management system meaning, types and GxP requirements

An EDMS (electronic document management system) is the software that controls a regulated company's procedures, specifications and records from draft to retirement. This guide covers the meaning and full form, the five types, the 21 CFR Part 11 and Annex 11 controls a GxP EDMS needs, the document lifecycle, how an EDMS differs from a QMS and a LIMS, and how often FDA cites document control on Form 483s.

FDA Consent Decrees Explained.

Atlas

Regulatory Intelligence

What Is a Consent Decree? FDA Consent Decrees Explained, With Examples

An FDA consent decree is a court order, usually a permanent injunction, that a company agrees to after the Department of Justice sues on FDA's behalf. This guide explains how a firm reaches one, what the decree requires, how long it lasts and how it ends, lists well-known FDA consent decrees from 2012 to 2024, and shows the inspection record behind three of them.

OOS Meaning: Out of Specification

Atlas

Regulatory Intelligence

OOS Meaning in Pharma: Out of Specification Results, OOS vs OOT, and the FDA Investigation

OOS stands for Out of Specification, a test result that falls outside the approved acceptance criteria. This guide explains the OOS meaning in pharma, how it differs from OOT, the phase I laboratory and phase II full-scale investigation in FDA's OOS guidance, the rules on retesting, resampling and averaging, and how often FDA cites 21 CFR 211.192 and 211.160 in drug inspections, with named 2025 and 2026 Form 483 examples.

US FDA Investigator List

Atlas

Regulatory Intelligence

US FDA investigator list: where the names come from and how to look one up

FDA publishes no public roster of its investigators or auditors. This guide shows where investigator names do appear (credentials, Form FDA 482, the Form 483 signature block, the EIR and FOIA releases), how to look an investigator up in the Atlas directory of 4,996 profiles, which investigators signed the most Form 483s in 2025 and 2026, and how to use an investigator's record in the weeks before an inspection.

CAPA Effectiveness Checks and Metrics

Atlas

Regulatory Intelligence

CAPA Effectiveness Checks and Metrics: How to Prove a Fix Worked

A CAPA effectiveness check proves that the problem behind a CAPA did not come back. This guide separates effectiveness from verification, sets out the four fields every check needs, compares the methods that produce real evidence, explains sample size and confidence, scales rigor to risk, lists the program-level CAPA effectiveness metrics, and shows what FDA cites when effectiveness is missing, using Atlas Form 483 data and two warning letters. A copyable planning template is included.

Regulatory Intelligence

What Is an FDA Form 483? Observations, Responses, and What Happens Next

An FDA Form 483 is the list of inspectional observations an FDA investigator hands to management at the close of an inspection. This guide covers what a 483 contains, how many FDA issues each year, what a typical one looks like, how to respond within 15 business days, and how a 483 turns into a VAI, OAI, or warning letter.